Boscá I - Search Results

1

Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.

Pascual AM, Boscá I, Coret F, Escutia M, Bernat A, Casanova B. Pascual AM, et al. Among authors: bosca i. Eur J Neurol. 2008 Mar;15(3):284-8. doi: 10.1111/j.1468-1331.2008.02061.x. Eur J Neurol. 2008. PMID: 18290849 Clinical Trial.

2

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study.

Magraner MJ, Coret F, Navarré A, Boscá I, Simó M, Escutia M, Bernad A, Navarro L, Casanova B. Magraner MJ, et al. Among authors: bosca i. J Neurol. 2011 Oct;258(10):1805-11. doi: 10.1007/s00415-011-6019-8. Epub 2011 Apr 6. J Neurol. 2011. PMID: 21625938 Clinical Trial.

3

Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis.

Pascual AM, Martínez-Bisbal MC, Boscá I, Valero C, Coret F, Martínez-Granados B, Marti-Bonmati L, Mir A, Celda B, Casanova B. Pascual AM, et al. Among authors: bosca i. Neurology. 2007 Jul 3;69(1):63-7. doi: 10.1212/01.wnl.0000265054.08610.12. Neurology. 2007. PMID: 17606882

4

[Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data].

Pascual AM, Boscá I, Escutia M, Bernat A, Coret F, Casanova B. Pascual AM, et al. Among authors: bosca i. Neurologia. 2008 Mar;23(2):73-7. Neurologia. 2008. PMID: 17641984 Clinical Trial. Spanish.

5

Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.

Bosca I, Coret F, Valero C, Pascual AM, Magraner MJ, Landete L, Casanova B. Bosca I, et al. Mult Scler. 2008 Jun;14(5):636-9. doi: 10.1177/1352458507086666. Mult Scler. 2008. PMID: 18566027 Clinical Trial.

6

Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone.

Bosca I, Pascual AM, Casanova B, Coret F, Sanz MA. Bosca I, et al. Neurology. 2008 Aug 5;71(6):457-8. doi: 10.1212/01.wnl.0000324422.69067.e7. Neurology. 2008. PMID: 18678830 No abstract available.

7

Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.

Bosca I, Villar LM, Coret F, Magraner MJ, Simó-Castelló M, Alvarez-Cermeño JC, Casanova B. Bosca I, et al. Mult Scler. 2010 Jul;16(7):810-5. doi: 10.1177/1352458510371961. Epub 2010 Jun 10. Mult Scler. 2010. PMID: 20538705

8

Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.

Alcalá C, Gascón F, Pérez-Miralles F, Gil-Perotín S, Navarré A, Boscá I, Coret F, Casanova B. Alcalá C, et al. Among authors: bosca i. J Neurol. 2018 Jul;265(7):1690-1697. doi: 10.1007/s00415-018-8899-3. Epub 2018 May 21. J Neurol. 2018. PMID: 29785523

9

Necrotising cutaneous lesions as a side effect of glatiramer acetate.

Bosca I, Bosca M, Belenguer A, Evole M, Hernandez M, Casanova B, Coret F. Bosca I, et al. Among authors: bosca m. J Neurol. 2006 Oct;253(10):1370-1. doi: 10.1007/s00415-006-0233-9. Epub 2006 Jun 13. J Neurol. 2006. PMID: 16773267 No abstract available.

10

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

Pascual AM, Téllez N, Boscá I, Mallada J, Belenguer A, Abellán I, Sempere AP, Fernández P, Magraner MJ, Coret F, Sanz MA, Montalbán X, Casanova B. Pascual AM, et al. Among authors: bosca i. Mult Scler. 2009 Nov;15(11):1303-10. doi: 10.1177/1352458509107015. Epub 2009 Oct 13. Mult Scler. 2009. PMID: 19825889

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters